Aciclovir treatment for human immunodeficiency virus-1: Is the "juice worth the squeeze?"

Sexually Transmitted Diseases

Volumn 38, Issue 5, 2011, Pages 410-412

  Cohen, Myron S ^a   Eron Jr , Joseph J ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; PLACEBO;

ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; COST BENEFIT ANALYSIS; DRUG EFFICACY; EDITORIAL; HERPES SIMPLEX VIRUS 2; HERPES VIRUS INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MIXED INFECTION; VIREMIA; VIRUS LOAD; VIRUS SHEDDING; VIRUS TRANSMISSION;

ACYCLOVIR; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; COINFECTION; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; HERPES GENITALIS; HERPESVIRUS 2, HUMAN; HIV INFECTIONS; HUMANS; MALE; TREATMENT OUTCOME;

EID: 79954800357     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/OLQ.0b013e318214b6e1     Document Type: Editorial

References (29)

1. Weiss H. Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes 2004; 11(suppl 10):24A- 35A. (Pubitemid 38529332)
2. Ioannidis JP, Collier AC, Cooper DA, et al. Clinical efficacy of high-dose acyclovir in patients with human immunodeficiency virus infection: A meta-analysis of randomized individual patient data. J Infect Dis 1998; 178:349-359. (Pubitemid 28347916)
3. Celum C, Wald A, Lingappa JR, et al. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med 2010; 362:427-439.
4. Lingappa JR, Baeten JM, Wald A, et al. Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: A randomised placebo-controlled trial. Lancet 2010; 375:824-833.
5. Vickerman P, Devine A, Foss AM, et al. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa. Sex Transm Dis 2011; 38:401-409.
6. Wald A, Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: A meta-analysis. J Infect Dis 2002; 185:45-52. (Pubitemid 34043015)
7. Nagot N, Ouedraogo A, Foulongne V, et al. Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus. N Engl J Med 2007; 356:790-799. (Pubitemid 46294611)
8. Phiri S, Hoffman IF, Weiss, HA, et al. Impact of acyclovir on ulcer healing, lesional and genital and plasma HIV-1 RNA among patients with genital ulcer disease in Malawi. Sex Transm Infect 2010; 86:345-352.
9. Galvin SR, Cohen MS. Sexual transmission of HIV. Nat Rev Microbiol 2004; 2:33-42.
10. Celum C, Wald A, Hughes J, et al. Effect of acyclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: A randomised, double-blind, placebo-controlled trial. Lancet 2008; 371:2109-2119. (Pubitemid 351902179)
11. Watson-Jones D, Weiss HA, Rusizoka M, et al. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania. N Engl J Med 2008; 358:1560-1571. Erratum in: N Engl J Med 2010; 362:1450. (Pubitemid 351519816)
12. Kim HN, Wang J, Hughes J, et al. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection. J Infect Dis 2010; 202:734-738.
13. Tanton C, Weiss HA, Rusizoka M, et al. Long-term impact of acyclovir suppressive therapy on genital and plasma HIV RNA in Tanzanian women: A randomized controlled trial. J Infect Dis 2010; 201:1285-1297.
14. Fuchs J, Celum C, Wang J, et al. Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial. J Infect Dis 2010; 201:1164-1168.
15. Zhu J, Hladik F, Woodward A, et al. Persistence of HIV-1 receptor-positive cells after HSV-2 reactivation is a potential mechanism for increased HIV-1 acquisition. Nat Med 2009; 15:886-892.
16. Corey L, Wald A, Patel R, et al. Once-daily valacyclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004; 350:11-20. (Pubitemid 38032179)
17. McMahon MA, Silicano JD, Lai J, et al. The antiherpetic drug acyclovir inhibits HIV replication and selects the V751 reverse transcriptase multidrug resistance mutation. J Biol Chem 2008; 283:1289-1293.
18. Gray RH, Wawer MJ. Reassessing the hypothesis on STI control for HIV prevention. Lancet 2008; 371:2064-2065. (Pubitemid 351842568)
19. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: The contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect 1999; 75:3-17. (Pubitemid 29117474)
20. Bunnell R, Ekwaru JP, Solberg P, et al. Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS 2006; 20: 85-92. (Pubitemid 41818118)
21. Funk MJ, Fusco JF, Cole, et al; for the CASCADE Collaboration. HAART initiation and clinical outcomes: Insights from the CASCADE cohort of HIV-1 seroconverters on "When to Start." Presented at: XVIII International AIDS Conference; July 18-23 2010; Vienna, Austria. Oral Late Breaker Presentation.
22. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: A prospective cohort analysis. Lancet 2010; 375:2092-2098.
23. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents [AIDSinfo/NIH Website]. January 10, 2011. Available at: http://www.aidsinfo.nih.gov/ ContentFiles/AdultandAdolescentGL. pdf. Accessed January 18, 2011.
24. European AIDS Clinical Society. Clinical management and treatment of HIV-infected adults in Europe [EACS Website]. June 2, 2003. Available at: http://www.europeanaidsclinicalsociety.org/ guidelines.asp. Accessed May 26, 2010.
25. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
26. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
27. Burns DN, Dieffenbach CW, Vermund SH. Rethinking prevention of HIV type 1 infection. Clin Infect Dis 2010; 51:725-731.
28. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304: 321-333.
29. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach: 2010 Revision [WHO Website]. 2010. Available at: http://whqlibdoc.who.int/ publications/2010/9789241599764- eng.pdf. Accessed January 18, 2011.